Chest
Volume 134, Issue 1, July 2008, Pages 1-2
Journal home page for Chest

Editorials
Coexisting Asthma and COPD: Confused Clinicians or Poor Prognosticator?

https://doi.org/10.1378/chest.08-0365Get rights and content

References (12)

There are more references available in the full text version of this article.

Cited by (6)

  • Comorbidome, pattern, and impact of asthma-COPD overlap syndrome in real life

    2016, Chest
    Citation Excerpt :

    We used all comorbidities as available in the administrative database, but not validated indices such as the Charlson comorbidity index34 or COTE (COPD specific comorbidity test) index.27 Finally, note that patients with more health-care use may have more chance to get a double diagnosis.35 To date, a number of literature reviews have covered ACOS, including its pharmacotherapy and physiological properties.6,10,23,36-40

  • The asthma-COPD overlap syndrome: Towards a revised taxonomy of chronic airways diseases?

    2015, The Lancet Respiratory Medicine
    Citation Excerpt :

    When ACOS is defined on the basis of a doctor diagnosis of both asthma and COPD, its prevalence in different cohorts of patients aged 40 years and older with chronic airways disease—including the US NHANES III study,14 the UK GP Research Database,15 and other studies in the USA,16 Italy,11 and Finland12—is in the range of 15–20%. However, in patients with chronic asthma, physicians are probably biased towards adding a diagnosis of COPD with increasing age and in those who have features of chronic irreversible airflow limitation, are symptomatic with this disease and therefore need additional treatment.17 This tendency is suggested by the lower proportions diagnosed with asthma alone in older age groups (eg, 65–84 years) than in younger age groups (eg, 20–44 years).11

  • Understanding COPD-overlap syndromes

    2017, Expert Review of Respiratory Medicine
  • Significant bronchodilator responsiveness and "reversibility" in a population sample

    2010, COPD: Journal of Chronic Obstructive Pulmonary Disease

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).

1

Dr. Mannino is from the Department of Preventive Medicine and Environmental Health, University of Kentucky College of Public Health.

2

Dr. Mannino has received research grants from GlaxoSmithKline, Pfizer, and Novartis, and serves as a consultant to GlaxoSmithKline, Pfizer, Boehringer-Ingelheim, Astra-Zeneca, Dey, Sepracor, and Novartis.

View full text